NCT01262911View on ClinicalTrials.gov

Effect of SRT2379 on Endotoxin-Induced Inflammation

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

February 17, 2011

Primary Completion Date

April 26, 2011

Study Completion Date

April 26, 2011

Conditions
Sepsis
Interventions
DRUG

SRT2379

SRT2379 will be supplied as hard gelatin capsules, with each containing 250mg.

DRUG

Placebo

Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.

Trial Locations (1)

1105 AZ

GSK Investigational Site, Amsterdam

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Sirtris, a GSK Company

INDUSTRY

NCT01262911 - Effect of SRT2379 on Endotoxin-Induced Inflammation | Biotech Hunter | Biotech Hunter